Tempus AI - Class A opened lower at $73.26, compared with its previous close of $77.84. In the last trading session, the stock traded between $71.75 and $76.65. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Tempus AI - Class A is now worth
$ 178.26
giving a profit of
$ 78.26 (78.26%)
Note: Past profits do not guarantee future returns.
Rating from 15 Analysts
Today's Change
$-6.09 (-7.82%)
Day High
$76.65
Day Low
$71.75
Day Open
$73.26
Prev Close
$77.84
Volume
29,07,310
1W Return
12.43%
1M Return
-13.17%
3M Return
72.69%
6M Return
43.44%
1Y Return
-19.24%
Market Cap ($ Mn)
12,714
PE Ratio
-
PB Ratio
25.94
PEG Ratio
-
ROE
-72.44%
ROCE
-16.96%
EPS (TTM)
-
1 Week
12.43%
1 Month
-13.17%
3 Months
72.69%
6 Months
43.44%
9 Months
12.98%
Tempus AI panel shows over 80% sensitivity in advanced lung cancer study
AI panel achieved >80% sensitivity across 12 biomarkers in advanced NSCLC study. Study analyzed 60,459 cases using routine H&E pathology images. Results presented at ESMO Congress 2026 in Madrid via Pfizer collaboration. Panel aims to prioritize testing and preserve limited tissue samples.
11 days agoTempus AI Q3FY26 Results: Earnings call set for November 2, 2026
Tempus AI reports Q3FY26 results on November 2, 2026. Conference call scheduled for 8:45 am ET. Call led by CEO Eric Lefkofsky and CFO Jim Rogers. Webcast available via investor relations website.
14 days agoTempus AI expands Moderna, Merck cancer vaccine infrastructure deal
Tempus AI expands multi-year collaboration with Moderna and Merck for intismeran autogene commercialization. Agreement includes managing tumor tissue collection and providing next-generation sequencing services. Tempus AI acquired Personalis, Inc. for $1.5 billion in July to enhance minimal residual disease capabilities. Shares traded at $70.58, down 1.94%, despite earlier recovery from acquisition-related sell-off.
22 days agoTempus, Recursion extend data license to 2029 with $42 million commitment
Tempus AI and Recursion Pharmaceuticals extended their data partnership through November 2029. The amendment replaces potential $84 million in discretionary fees with $42 million in committed payments. Tempus secured a non-exclusive worldwide license to Recursion’s RNA Foundation Model "TxFM". The collaboration, started in 2023, focuses on using foundation models for precision medicine.
1mo agoTempus AI stock falls 4.49% after rally on reimbursement outlook
Tempus AI stock fell 4.49% to $76.75 on Friday amid broader market weakness. CEO Eric Lefkofsky projected $80 million-$100 million benefit from new solid-tumor assay pricing starting Jan. 1. Liquid-biopsy test approval expected in H2 2027 could add $250 million-$300 million in revenue and margin benefit. Stock remains 16% above its 20-day SMA and 35% above its 50-day SMA. Consensus analyst rating is Hold with an average price target of $67.08.
1mo agoTempus CEO Eric Lefkofsky to speak at Morgan Stanley healthcare conference
Tempus AI CEO Eric Lefkofsky to speak at Morgan Stanley conference. Fireside chat scheduled for September 15, 2026, in New York City. Live audio webcast of the session will be available online.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $478.08 | +3.21% | $1,03,505.28M | 14.01 | |
| $310.34 | -2.35% | $50,246.84M | 45.36 | |
| $270.57 | +0.77% | $21,786.03M | 10.31 | |
| $131.49 | +7.70% | $12,971.88M | 20.21 | |
| $23.13 | +2.25% | $12,423.82M | 11.93 | |
| $193.31 | +5.10% | $12,333.18M | 15.26 | |
| $60.22 | +1.28% | $11,915.37M | 52.31 | |
| $186.32 | +1.20% | $10,870.10M | 27.11 | |
| $176.61 | +2.57% | $9,128.62M | 7.00 | |
| $101.36 | +0.02% | $8,383.99M | 34.79 | |
| $49.68 | +1.26% | $7,866.13M | 25.00 | |
| $116.90 | +1.41% | $7,302.63M | 28.83 |
An investment of $100 made 3 years ago in Tempus AI - Class A is now worth
$ 178.26
giving a profit of
$ 78.26 (78.26%)
Note: Past profits do not guarantee future returns.
